IDH2 and B-cell non-Hodgkin lymphoma: IDH2 inhibitors are naturally being developed for IDH2-mutant leukemia, EZH2 inhibitors are being studied in EZH2-altered B-cell lymphoma, and our BET inhibitors are actively being studied in BET-rearranged lung cancer and BET-rearranged head and neck cancer (so-called NUT midline carcinoma).